1-Methylamino-hexamethylenimin | 91772-90-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 英文名称: 1-Methylamino-hexamethylenimin
• 英文别名: azepan-1-yl-methyl-amine；N-methylazepan-1-amine
• CAS: 91772-90-6
• 化学式: C₇H₁₆N₂
• 分子量: 128.217
• InChiKey: KJQBETZNYWESCI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• THERAPEUTIC AGENT FOR CEREBRAL INFARCTION
  申请人：Nakao Akira

  公开号：US20120196824A1

  公开（公告）日：2012-08-02

  The invention provides a therapeutic drug for ischemic stroke. The therapeutic drug has the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof, as an active ingredient.

  这项发明提供了一种用于缺血性中风的治疗药物。该治疗药物具有如下式（I）的化学式，其中每个符号如本文所定义，或其药理学上可接受的盐，或其溶剂化物，作为活性成分。
• Process for producing 1-alkoxycarbonyl nitrogenous saturated heterocyclic derivative
  申请人：——

  公开号：US20040242888A1

  公开（公告）日：2004-12-02

  A method for producing N-protected heterocyclic compounds such as 1-alkoxycarbonyl-3-aminopyrrolidines through position-selective reaction at the nitrogen atom that constitutes the hetero ring of a nitrogen-containing saturated heterocyclic compound having two nitrogen atoms such as 3-aminopyrrolidine. A dialkyl dicarbonate (ROCO-O-COOR) is reacted with a nitrogen-containing saturated heterocyclic compounds having two nitrogen atoms, at pH of from 9 to 14 to obtain a high-purity 1-alkoxycarbonyl nitrogen-containing saturated heterocyclic compound.

  一种生产N-保护杂环化合物（例如1-烷氧羰基-3-氨基吡咯烷）的方法，通过在含有两个氮原子的氮杂环化合物（例如3-氨基吡咯烷）的杂环中构成氮原子的位置选择性反应。将双烷基碳酸酯（ROCO-O-COOR）与含有两个氮原子的氮杂环化合物在pH为9至14的条件下反应，可获得高纯度的1-烷氧羰基氮杂环化合物。
• Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity
  申请人：Moritani Yasunori

  公开号：US20090048256A1

  公开（公告）日：2009-02-19

  The present invention relates to a pyrazole compound having potent CB1-antagonizing activity, having the following formula [I]: wherein R 1 and R 2 are the same or different and an optionally substituted aryl group etc., R 3 is an alkyl group etc., E is one of the following groups of the formula (i) to (iv): Q 1 is a single bond, an alkylene group or a group of the formula: —N(R 7 )—, R 7 is a hydrogen atom or an alkyl group, Q 2 is a single bond, an oxygen atom or an alkylene group, R 4 is a cycloalkyl group, a group of the formula: —N(R 5 )(R 6 ) etc., one of R 5 and R 6 is a hydrogen atom or an alkyl group and the other is an alkyl group, a group of the formula: —N(R 8 )(R 9 ) etc., D is an oxygen atom etc., R A1 is an amino group etc., R A2 is an optionally substituted aliphatic heterocyclic group, R is an alkyl group optionally substituted by one to three halogen atom(s) etc., one of R 8 and R 9 is a hydrogen atom or an alkyl group and the other is an alkyl group etc., or a pharmaceutically acceptable salt thereof.

  本发明涉及一种具有强效CB1拮抗活性的吡唑化合物，具有以下式[I]：其中R1和R2相同或不同，且可以是取代的芳基等，R3是烷基等，E是以下式(i)至(iv)中的一种基团：Q1是单键，烷基或式：—N（R7）—的基团，R7是氢原子或烷基，Q2是单键，氧原子或烷基，R4是环烷基，式：—N（R5）（R6）等的基团，其中R5和R6中的一个是氢原子或烷基，另一个是烷基，式：—N（R8）（R9）等的基团，D是氧原子等，RA1是氨基等，RA2是可选取代的脂肪族杂环基团，R是烷基，可选取代为1至3个卤原子等，R8和R9中的一个是氢原子或烷基，另一个是烷基等，或其药学上可接受的盐。
• Pyrazolo[1,5-A]Pyrimidine Compounds
  申请人：Moritani Yasunori

  公开号：US20090069298A1

  公开（公告）日：2009-03-12

  The present invention relates to a novel pyrazolo[1,5-a]pyrimidine compound of the formula [I]: wherein R 1 and R 2 are the same or different and an optionally substituted aryl group etc. Q is single bond, a methylene group or a group of the formula: —N(R Q )—, R Q is an alkyl group, Ring A is a substituted pyrazole ring fused to the adjacent pyrimidine ring having the following formula (A), (B) or (C), R 3 and R 4 are the same or different and a hydrogen atom, a cyano group etc. E is one of the following groups (i) to (v): R 00 is an alkyl group, Q 1 is a single bond etc., Q 2 is a single bond or an alkylene group, one of R 5 and R 6 is a hydrogen atom or an alkyl group and the other is an alkyl group etc., one of R 50 and R 60 is a hydrogen atom or an alkyl group and the other is a hydrogen atom, an alkyl group etc., R 51 is an alkyl group or an optionally substituted arylsulfonyl group, R 61 is an alkylamino group or an azido group, or a pharmaceutically acceptable salt thereof.

  本发明涉及一种新型吡唑并[1,5-a]嘧啶化合物，其化学式为[I]：其中R1和R2相同或不同，可以是任选取代芳基等；Q是单键，亚甲基基团或式子：—N(RQ)—，RQ是烷基基团；环A是一个取代的吡唑环与相邻的嘧啶环融合，具有以下式子(A)、(B)或(C)：其中R3和R4相同或不同，可以是氢原子、氰基等；E是以下式子(i)至(v)中的一种：其中R00是烷基基团，Q1是单键等，Q2是单键或烷基烃基团，R5和R6中的一个是氢原子或烷基基团，另一个是烷基基团等，R50和R60中的一个是氢原子或烷基基团，另一个是氢原子、烷基基团等，R51是烷基基团或任选取代的芳基磺酰基团，R61是烷基氨基基团或叠氮基团，或其药学上可接受的盐。
• SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-1 MODULATORS
  申请人：Baker Robert K.

  公开号：US20100317645A1

  公开（公告）日：2010-12-16

  Certain novel substituted diazepine sulfonamides are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.

  某些新型取代二氮杂环磺酰胺是人体炸弹素受体的配体，特别是人体炸弹素受体亚型-3（BRS-3）的选择性配体。因此，它们可用于治疗、控制或预防对BRS-3调节敏感的疾病和障碍，如肥胖和糖尿病。